Busse lectures highlight PEGylation and History of Biomaterials & Medical Devices

Dr. Allan Hoffman

Dr. Allan Hoffman Professor Emeritus, Department of Bioengineering University of Washington, Seattle, will deliver the 2017 Busse Lectures on Thursday and Friday, September 14 and 15.

Hoffman will deliver “Update on PEG and PEGylation,” on Thursday, September 14 at 4:00 p.m. in Room 2002 Rennebohm Hall. The talk will be of special interest to those in the scientific community. A second lecture, “History of Biomaterials & Medical Devices,” will be geared toward the lay community and will be held Friday, September 15 at 3:30 p.m. in Room 2006 Rennebohm Hall. Receptions will be held immediately following each lecture.

Professor Hoffman studied at M.I.T., where he received his BS, MS, and ScD degrees in Chemical Engineering between 1949 and 1957. He taught on the faculty of the M.I.T. Chemical Engineering Department for a total of ten years. He has been Professor Emeritus of Bioengineering at the University of Washington in Seattle since 1970.

Hoffman has been honored for his contributions to the field through professional activities and awards including President, Society for Biomaterials (1983-1984), Biomaterials Science Prize, Japanese Biomaterials Society (1990), Founders’ Award of the Society for Biomaterials (2000), Elected to the National Academy of Engineering (2005), International Recognition Award, Society for Polymer Science, Japan (2006), Founders’ Award of the Controlled Release Society (2007), and Acta Biomaterialia Gold Medal Award (2017).

Hoffman is retired but continues to actively teach and advise on research in the areas of biomaterials, smart polymers, hydrogels, drug delivery, affinity separations, and biomaterial surface modification.

Established in 1979 in honor of Dr. Louis W. Busse and his many contributions to the School of Pharmacy, his profession, and to pharmaceutical research, the Busse Lectureship is intended to bring speakers to the School of Pharmacy who have a fundamental research interest combined with a strong knowledge of the industrial pharmaceutical research environment.